Nancy Lin: Palazestrant Demonstrates More Than 7 Months mPFS in EMERALD-Eligible ER+ MBC Patients
Nancy Lin, Breast Cancer Specialist and Director of EMBRACE MBC Program at Dana-Farber Cancer Institute, shared a post on X about a paper she co-authored with colleagues published in Breast Cancer Research:
“Now published!
Phase 1/2 palazestrant (OP-1250) monotherapy in ER+ MBC
- at RP2D 120 mg/d
- mPFS 4.8 mo overall, 5.6 mo in ESR1mut
- in ‘EMERALD eligible’ patients (1-2 prior ET for MBC +/- 1L chemo), mPFS > 7 mo regardless of ESR1 status.”
Title: Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results
Authors: Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, and Nancy U. Lin.
You can read the Full Article in Breast Cancer Research.
More posts featuring Nancy Lin.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023